3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
NCT ID: NCT00275444
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
216 participants
INTERVENTIONAL
2002-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tipranavir
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Human immunodeficiency virus 1 (HIV-1) infected males or females \> 18 years of age.
* At least 3 months experience taking Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitor (NNRTIs), and Protease inhibitors (PIs).
* Current PI-based Antiretroviral (ARV) medication regimen for at least 3 months prior to randomization, and at least 3 months experience taking at least one other PI-based regimen.
* HIV-1 viral load ≥1000 copies/mL at screening.
* Genotypic resistance report indicating one or more primary PI resistance mutation(s), including 30N, 46I/L, 48V, 50V, 82A/F/T, 84V or 90M.
* Availability of 2 or more non-PI ARV medications by genotypic resistance testing, i.e. 2 drugs tested as "no evidence of resistance" or "possible resistance".
* Acceptable screening laboratory values that indicate adequate baseline organ function.
* Laboratory values are considered to be acceptable if severity is no higher than Grade 3 Gamma glutamyl transferase (GGT), Grade 2 cholesterol or triglycerides, and no higher than Grade 1 for all other tests based on the "Division of Acquired Immune Deficiency Syndrome" of National Institute of Health, USA - DAIDS - Grading Scale. All laboratory values outside these limits are subject to approval by Boehringer Ingelheim (BI).
Exclusion Criteria
* Only one or no available ARV medications as determined by genotypic resistance testing.
* Female subjects who:
* have a positive serum pregnancy test at screening or during the study;
* are breast feeding;
* are planning to become pregnant;
* are not willing to use two methods of contraception to include at least one barrier method (e.g. latex condom plus spermicidal jelly/foam).
* Any active opportunistic infection within 60 days before study entry.
* Active Hepatitis B (HCB) or Hepatitis C (HCV) disease defined as HBsAg positive or HCV RNA positive with Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) \> Grade 1.
* Prior tipranavir use.
* Use of investigational medications within 30 days before study entry or during the trial.Some expanded access drugs may be acceptable; must be approved by BI. Tenofovir, investigational at time of preparation of this protocol, is acceptable.
* Use of concomitant drugs which may significantly reduce plasma levels of the study medications.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boehringer Ingelheim Investigational Site
Phoenix, Arizona, United States
Boehringer Ingelheim Investigational Site
Fountain Valley, California, United States
Living Hope Clinical Trials, Inc.
Long Beach, California, United States
Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
Vincent Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Therafirst Medical Center
Fort Lauderdale, Florida, United States
1501 N.W. 9th Ave
Miami, Florida, United States
Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
Boehringer Ingelheim Investigational Site
South Miami, Florida, United States
Hillsborough County Health Dept.
Tampa, Florida, United States
Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
Atlanta VA Medical Center
Decatur, Georgia, United States
Mercer University School of Medicine
Macon, Georgia, United States
CORE Center
Chicago, Illinois, United States
Rush-Presbytarian-St Luke's Medical Center
Chicago, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
HIV Outpatient Program (H.O.P)
New Orleans, Louisiana, United States
John's Hopkins University
Baltimore, Maryland, United States
Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
Community Research Initiative of New England
Springfield, Massachusetts, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
Washington University
St Louis, Missouri, United States
Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
ID Care
Hillsborough, New Jersey, United States
Boehringer Ingelheim Investigational Site
Santa Fe, New Mexico, United States
Albany Medical College
Albany, New York, United States
University of New York at Stony Brook
Stony Brook, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Boehringer Ingelheim Investigational Site
Huntersville, North Carolina, United States
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Boehringer Ingelheim Investigational Site
Oklahoma City, Oklahoma, United States
Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
Boehringer Ingelheim Investigational Site
Houston, Texas, United States
Boehringer Ingelheim Investigational Site
Annandale, Virginia, United States
Boehringer Ingelheim Investigational Site
Darlinghurst, New South Wales, Australia
St. Vincent's Hospital
Darlinghurst, New South Wales, Australia
Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
Montreal Chest Institute - McGill University Health Centre
Montreal, Quebec, Canada
Hôpital de Bicêtre
Le Kremlin-Bicêtre, , France
Hôpital de Chauliac
Montpellier, , France
Hôpital Hôtel Dieu
Nantes, , France
Hôpital Bichat Claude Bernard
Paris, , France
Hôpital de la pitié Salpetrière
Paris, , France
Hôpital Saint Louis
Paris, , France
Epimed GmbH
Berlin, , Germany
Klinik I für Innere Medizin der
Cologne, , Germany
Klinikum der J.-W.-Goethe-Universität
Frankfurt am Main, , Germany
Medizinische Poliklinik
München, , Germany
Fondazione Centro S. Raffaele del Monte Tabor
Milan, , Italy
IRCCS Policlinico San Matteo
Pavia, , Italy
Academisch Medisch Centrum
Amsterdam, , Netherlands
Erasmus Medical Centre
Rotterdam, , Netherlands
Hospital Clínico y Provincial de Barcelona - HIV
Barcelona, , Spain
Boehringer Ingelheim Investigational Site
Madrid, , Spain
Hospital La Paz.
Madrid, , Spain
Hospital Ramón y Cajal.
Madrid, , Spain
4th Floor Research Office (St Stephens Centre)
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1182.52
Identifier Type: -
Identifier Source: org_study_id